Edit
TargED Biopharmaceuticals
https://www.targedbiopharmaceuticals.com/Last activity: 18.12.2025
Active
TargED started in September 2018 and is currently developing one biopharmaceutical product: MICROLYSE. MICROLYSE enzymatically breaks down blood clots in small blood vessels (i.e. the microvasculature), for which to date, no specific treatment exists. TargED pursues to receive market authorization for an orphan disease named Thrombotic Thrombocytopenic Purpura (TTP) that is characterized by life threatening attacks of microvascular thrombosis. However, MICROLYSE has the capacity to target all forms of microvascular thrombosis and could also be applied in early-stage macrovascular thrombosis as seen in heart attacks and stroke.
Location: Netherlands
Employees: 1-10
Total raised: $69.42M
Founded date: 2018
Investors 5
| Date | Name | Website |
| - | Curie Capi... | curiecapit... |
| - | Fund+ | fundplus.b... |
| - | Andera Par... | anderapart... |
| - | Utrecht Ho... | utrechthol... |
| 08.03.2022 | Hadean Ven... | hadeanvent... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 18.12.2025 | - | $25.14M | Andera Par... |
| 24.02.2022 | Series A | $44.28M | - |
Mentions in press and media 10
| Date | Title | Description |
| 18.12.2025 | Dutch-based TargED raises €21.5 million Series A extension to advance targeted treatments for thrombotic diseases | Dutch clinical-stage BioTech company TargED Biopharmaceuticals has announced the closing of a €21.5 million Series A extension financing to accelerate the clinical development of its targeted thrombolytic, TGD001. The round was led by BioGe... |
| 03.11.2025 | TargED Biopharmaceuticals to Present First Clinical and New Preclinical Data on TGD001 in Two Oral Sessions at the 2025 ASH Annual Meeting | Utrecht, November 3, 2025 – TargED Biopharmaceuticals B.V., a clinical-stage biotechnology company developing next-generation targeted treatments for thrombotic diseases, today announced that first clinical and new preclinical data on its l... |
| 21.12.2023 | Hadean Ventures announces oversubscribed final close of Hadean Capital II | Hadean Ventures announces oversubscribed final close of Hadean Capital II – a fund dedicated to investments in life science start-ups across Europe Oslo, 21 December 2023. Hadean Ventures announced today the final close of Hadean Capital I... |
| 30.12.2022 | Dutch-based biotech and life sciences startups that raised funding in 2022 | The Netherlands is swiftly rising to the top as a hub for healthcare and life sciences innovation. More and more Dutch startups are engaged in a range of cutting-edge initiatives, such as the creation of digital health tools, the developmen... |
| 24.02.2022 | Utrecht-based TargED Biopharmaceuticals raises €39M, to target clinical development of thrombolytic treatment | TargED Biopharmaceuticals, an Utrecht-based biotechnology company focused on developing improved treatments for thrombotic diseases, announced that it has secured €39M in a Series A round of funding. The capital was provided by an internati... |
| 22.02.2022 | TargED Biopharmaceuticals raises EUR 39 Million in Series A financing | TargED Biopharmaceuticals raises EUR 39 Million in Series A financing to bring groundbreaking thrombolytic treatment to patients • Financing with equal contribution by an international investor syndicate comprising of Andera Partners, Fu... |
| 22.02.2022 | TargED Biopharmaceuticals raises EUR 39 Million in Series A financing to bring groundbreaking thrombolytic treatment to patients | TargED Biopharmaceuticals raises EUR 39 Million in Series A financing to bring groundbreaking thrombolytic treatment to patients |
| 22.02.2022 | Andera Partners supports TargED Biopharmaceuticals in €39 million Series A financing to bring groundbreaking thrombolytic treatment to patients | TargED Biopharmaceuticals (“TargED”), a private biotechnology company focused on developing improved treatments for thrombotic diseases, today announces it has raised Series A financing of EUR 39 million to accelerate development of its lea... |
| 22.02.2022 | TargED Biopharmaceuticals Raises €39M in Series A Financing | TargED Biopharmaceutical, a Utrecht, The Netherlands-based private biotechnology company focused on developing improved treatments for thrombotic diseases, raised €39M in Series A funding. The round was led by Andera Partners, Fund+, Hadean... |
| - | TargED Biopharmaceuticals | “Home - TargED” |